FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135966613> ?p ?o ?g. }

• W3135966613 abstract "ABSTRACT Background The efficacy and safety profile of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have not been definitively established in immunocompromised patient populations. Patients with a known cancer diagnosis were hitherto excluded from trials of the vaccines currently in clinical use. Methods This study presents data on the safety and immune efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine in 54 healthy controls and 151 mostly elderly patients with solid and haematological malignancies, respectively, and compares results for patients who were boosted with BNT162b2 at 3 weeks versus those who were not. Immune efficacy was measured as antibody seroconversion, T cell responses, and neutralisation of SARS-CoV-2 Wuhan strain and of a variant of concern (VOC) (B.1.1.7). We also collected safety data for the BNT162b2 vaccine up to 5 weeks following first dose. Findings The vaccine was largely well tolerated. However, in contrast to its very high performance in healthy controls (>90% efficacious), immune efficacy of a single inoculum in solid cancer patients was strikingly low (below 40%) and very low in haematological cancer patients (below 15%). Of note, efficacy in solid cancer patients was greatly and rapidly increased by boosting at 21-days (95% within 2 weeks of boost). Too few haematological cancer patients were boosted for clear conclusions to be drawn. Conclusions Delayed boosting potentially leaves most solid and haematological cancer patients wholly or partially unprotected, with implications for their own health; their environment and the evolution of VOC strains. Prompt boosting of solid cancer patients quickly overcomes the poor efficacy of the primary inoculum in solid cancer patients. RESEARCH IN CONTEXT Evidence before this study Some cancer patients have been shown to exhibit sustained immune dysregulation, inefficient seroconversion and prolonged viral shedding as a consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Consequently, their exclusion and, in particular, the exclusion of patients receiving systemic anti-cancer therapies, from the registry trials of the 5 approved COVID-19 vaccines raises questions about the efficacy and safety of SARS-CoV-2 vaccination in this patient population. In addition, whilst the change in the UK’s dosing interval to 12-weeks aimed to maximise population coverage, it is unclear whether this strategy is appropriate for cancer patients and those on systemic anti-cancer therapies. Added value of this study We report that the RNA-based SARS-CoV-2 BNT162b2 vaccine administered in cancer patients was well tolerated, and we provide first insights into both antibody and T cell responses to the vaccine in an immunocompromised patient population. Implications of all the available evidence In cancer patients, one dose of 30ug of BNT162b2 yields poor vaccine efficacy, as measured by seroconversion rates, viral neutralisation capacity and T cell responses, at 3- and 5-weeks following the first inoculum. Patients with solid cancers exhibited a significantly greater response following a booster at 21-days. These data support prioritisation of cancer patients for an early (21-day) second dose of the BNT162b2 vaccine. Given the globally poor responses to vaccination in patients with haematological cancers, post-vaccination serological testing, creation of herd immunity around these patients using a strategy of ‘ring vaccination’, and careful follow-up should be prioritised." @default.
• W3135966613 created "2021-03-29" @default.
• W3135966613 creator A5000168334 @default.
• W3135966613 creator A5000829593 @default.
• W3135966613 creator A5003141763 @default.
• W3135966613 creator A5003985815 @default.
• W3135966613 creator A5013066121 @default.
• W3135966613 creator A5014364684 @default.
• W3135966613 creator A5015902231 @default.
• W3135966613 creator A5018812698 @default.
• W3135966613 creator A5019091151 @default.
• W3135966613 creator A5025872990 @default.
• W3135966613 creator A5026343855 @default.
• W3135966613 creator A5034026446 @default.
• W3135966613 creator A5034738625 @default.
• W3135966613 creator A5034748028 @default.
• W3135966613 creator A5035272028 @default.
• W3135966613 creator A5035423417 @default.
• W3135966613 creator A5045820092 @default.
• W3135966613 creator A5048086477 @default.
• W3135966613 creator A5048120106 @default.
• W3135966613 creator A5049714548 @default.
• W3135966613 creator A5054111078 @default.
• W3135966613 creator A5056715948 @default.
• W3135966613 creator A5057065551 @default.
• W3135966613 creator A5061129114 @default.
• W3135966613 creator A5063315684 @default.
• W3135966613 creator A5069176195 @default.
• W3135966613 creator A5075689685 @default.
• W3135966613 creator A5075885901 @default.
• W3135966613 creator A5075959397 @default.
• W3135966613 creator A5077048880 @default.
• W3135966613 creator A5078531274 @default.
• W3135966613 creator A5078967449 @default.
• W3135966613 creator A5082171636 @default.
• W3135966613 creator A5084351864 @default.
• W3135966613 creator A5084722080 @default.
• W3135966613 creator A5087396508 @default.
• W3135966613 creator A5087403121 @default.
• W3135966613 creator A5089767652 @default.
• W3135966613 creator A5090201792 @default.
• W3135966613 creator A5090990111 @default.
• W3135966613 creator A5091115060 @default.
• W3135966613 date "2021-03-17" @default.
• W3135966613 modified "2023-10-17" @default.
• W3135966613 title "Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines" @default.
• W3135966613 cites W1980312663 @default.
• W3135966613 cites W1999211903 @default.
• W3135966613 cites W2020073562 @default.
• W3135966613 cites W3006533361 @default.
• W3135966613 cites W3045971896 @default.
• W3135966613 cites W3046695189 @default.
• W3135966613 cites W3048160337 @default.
• W3135966613 cites W3048434629 @default.
• W3135966613 cites W3049325061 @default.
• W3135966613 cites W3085486156 @default.
• W3135966613 cites W3088689466 @default.
• W3135966613 cites W3088949724 @default.
• W3135966613 cites W3090844627 @default.
• W3135966613 cites W3093667122 @default.
• W3135966613 cites W3094870207 @default.
• W3135966613 cites W3097738396 @default.
• W3135966613 cites W3099011804 @default.
• W3135966613 cites W3102798166 @default.
• W3135966613 cites W3107586775 @default.
• W3135966613 cites W3111255098 @default.
• W3135966613 cites W3111852762 @default.
• W3135966613 cites W3113031614 @default.
• W3135966613 cites W3120915765 @default.
• W3135966613 cites W3127900911 @default.
• W3135966613 cites W3127921995 @default.
• W3135966613 cites W3128154910 @default.
• W3135966613 cites W3129580280 @default.
• W3135966613 cites W3134208712 @default.
• W3135966613 doi "https://doi.org/10.1101/2021.03.17.21253131" @default.
• W3135966613 hasPublicationYear "2021" @default.
• W3135966613 type Work @default.
• W3135966613 sameAs 3135966613 @default.
• W3135966613 citedByCount "40" @default.
• W3135966613 countsByYear W31359666132021 @default.
• W3135966613 countsByYear W31359666132022 @default.
• W3135966613 countsByYear W31359666132023 @default.
• W3135966613 crossrefType "posted-content" @default.
• W3135966613 hasAuthorship W3135966613A5000168334 @default.
• W3135966613 hasAuthorship W3135966613A5000829593 @default.
• W3135966613 hasAuthorship W3135966613A5003141763 @default.
• W3135966613 hasAuthorship W3135966613A5003985815 @default.
• W3135966613 hasAuthorship W3135966613A5013066121 @default.
• W3135966613 hasAuthorship W3135966613A5014364684 @default.
• W3135966613 hasAuthorship W3135966613A5015902231 @default.
• W3135966613 hasAuthorship W3135966613A5018812698 @default.
• W3135966613 hasAuthorship W3135966613A5019091151 @default.
• W3135966613 hasAuthorship W3135966613A5025872990 @default.
• W3135966613 hasAuthorship W3135966613A5026343855 @default.
• W3135966613 hasAuthorship W3135966613A5034026446 @default.
• W3135966613 hasAuthorship W3135966613A5034738625 @default.
• W3135966613 hasAuthorship W3135966613A5034748028 @default.
• W3135966613 hasAuthorship W3135966613A5035272028 @default.
• W3135966613 hasAuthorship W3135966613A5035423417 @default.
• W3135966613 hasAuthorship W3135966613A5045820092 @default.

• next